U.S. Markets closed

Coronavirus (COVID-19) Update: Daily Roundup

Coronavirus (COVID-19) Update: Daily Roundup

Coronavirus (COVID-19) Update: Daily Roundup

PR Newswire

SILVER SPRING, Md., June 17, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration today continued to take action in the ongoing response to the COVID-19 pandemic:

Additional Resources:

Media Contact: Lee.Herring@fda.hhs.gov, 240-402-6386
Consumer Inquiries: 888-INFO-FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

View original content to download multimedia:http://www.prnewswire.com/news-releases/coronavirus-covid-19-update-daily-roundup-301079111.html

SOURCE U.S. Food and Drug Administration

  • On June 16, 2020, the FDA approved an abbreviated new drug application for succinylcholine chloride injection USP 200 mg/10 mL, which is indicated, in addition to general anesthesia, to facilitate tracheal intubation and to induce skeletal muscle relaxation during surgery or mechanical ventilation. Side effects of succinylcholine chloride injection include anaphylaxis, hyperkalemia, and malignant hyperthermia.
  • The FDA recognizes the increased demand for certain products during the COVID-19 public health emergency, and we remain committed to facilitating access to safe and effective medical products to help address critical needs of the American public.
  • Today, the FDA published the Statistical Considerations for Clinical Trials During the COVID-19 Public Health Emergency Guidance for Industry. Clinical trials and development across investigational product areas have been impacted by public health measures to control the COVID-19 virus; this guidance shares recommendations on statistical considerations to address the impact of COVID-19 on meeting objectives of clinical trials conducted during this public health emergency. This guidance applies to clinical trials of human medical products and animal drugs.
  • Today, as part of its commitment to protect consumers and patients from fraudulent COVID-19 products and from the potential serious public health risks of these products, the FDA issued warning letters to three manufacturers: Medakit, Ltd., of Sheung Wan, Hong Kong; Antibodiescheck.com and Yama Group; and Dr. Jason Korkus, DDS, and Sonrisa Family Dental d/b/a My COVID19 Club of Chicago, Illinois. The warning letters were issued for marketing COVID-19 tests adulterated and misbranded COVID-19 antibody tests. Violations outlined in the letters include: offering test kits for sale in the United States directly to consumers for at-home use without marketing approval, clearance, or authorization from the FDA; misbranding products with labeling that falsely claims product are "FDA approved"; and labeling that bears the FDA logo, which is only for the official use by the FDA and not for use on private-sector materials. The FDA reminds the public that, at the present time, there are no diagnostic or antibody COVID-19 test kits that are currently authorized, cleared, or approved to be used completely at home. The FDA has authorized several diagnostic COVID-19 tests for use with at-home collection of samples (e.g., nasal, salivary) that can then be sent to a lab for processing and test reporting. However, there are not any antibody tests that are authorized for use with at-home collection of samples.
  • Testing updates:
U.S. Food and Drug Administration (FDA) logo (PRNewsfoto/FDA)
Cision